NEW YORK (360Dx) – OptiScan Biomedical today announced its OptiScanner 6000 device for near-continuous glucose and lactate monitoring has received CE mark, allowing the firm to market it in the European Union.
The Hayward, California-based firm said it plans to launch the device later this year.
The OptiScanner 6000 is an automated bedside monitoring technology that tracks levels of glucose and lactate within a single microsample of patient blood. According to OptiScan, the ability to measure lactate levels expands the capability of the device to optimize patient care in the ICU.
"By providing ICU physicians the means to serially monitor both lactate and glucose in the same, single microsample of the patient's blood, we believe that the OptiScanner 6000 will play an important role in continuing to elevate the level of care delivered to ICU patients," OptiScan Chairman and CEO Peter Rule said in a statement.